GEN Exclusives

More »

GEN News Highlights

More »
Oct 7, 2013

GSK Adds Another Program to Isis Antisense Collab

  • GlaxoSmithKline has added another drug candidate to its agreement with Isis Pharmaceuticals earning Isis $7 million in milestone payments. In March 2010 the two companies entered into an antisense collaboration potentially worth over $35 million that included up to six programs and focused on developing new therapeutics against targets for rare and/or serious diseases.

    According to the company, this latest candidate, ISIS-GSK3Rx, was designed to inhibit the production of an undisclosed target to treat a common viral infection. Isis will develop ISIS-GSK3Rx to Phase II  after which GSK has an exclusive option to in-license the program and further develop and commercialize the asset.

    As part of the agreement, Isis is eligible to receive additional prelicensing milestone payments from GSK as ISIS-GSK3Rx advances and double-digit royalties on sales of the candidate.

    In July, Isis won a $2 million milestone payment from GSK for the advancement of an ongoing Phase II/III study of ISIS-TTRRx, an antisense drug being developed by the firms as part of the alliance for the rare genetic disease transthyretin amyloidosis. In the deal, Isis received $20 million in up-front and milestone payments before the dosing of the first patient in the study, including a $7.5 million payment it earned in February upon initiation of the trial.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?